—

Liquidia Technologies Inc(LQDA)— 同業公司組

數據截至2026-10-08 — 評分每個交易日晚間重新計算。分組標準=首先為共同的Closelook指數成分,其次為產業。Closelook研究日記,不構成投資建議。

Liquidia Technologies Inc的Closelook綜合評分為45/100,在同業公司組內排名第11位(共11家)——組內評分最高的是Halozyme Therapeutics Inc(74/100)。

名稱綜合動能品質估值訊號距52週高點
LQDA Liquidia Technologies Inc45256838info70.1%
ROVI.MC Laboratorios Farmaceuticos ROVI61277752warn31.8%
LNTH Lantheus Holdings Inc60687457info10.5%
KNSA Kiniksa Pharmaceuticals Ltd57945921ok5.1%
AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock54895842ok7.2%
GALDY GALDERMA GROUP AG54445928info15%
ALM.MC Almirall S.A.53224668warn27.1%
HALO Halozyme Therapeutics Inc74949451ok6%
DXCM DexCom Inc66838037watch9%
ONC BeiGene, Ltd.64776432info9.1%
MEDP Medpace Holdings Inc63827530ok11.1%

評分為Closelook全部涵蓋範圍內的相對讀數——方法論詳見公司評分說明。訊號燈來自每日夜間訊號看板。

FAQ · from the current data · as of 2026-10-08

Quick answers

Liquidia Technologies Inc在Closelook涵蓋範圍內的同業公司有哪些?

分組首先根據共同的Closelook指數成分,其次根據產業:Laboratorios Farmaceuticos ROVI (ROVI.MC)、Lantheus Holdings Inc (LNTH)、Kiniksa Pharmaceuticals Ltd (KNSA)、Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)、GALDERMA GROUP AG (GALDY)、Almirall S.A. (ALM.MC)、Halozyme Therapeutics Inc (HALO)、DexCom Inc (DXCM)等。

LQDA相對同業公司的評分如何?

Liquidia Technologies Inc的綜合評分為45/100,組內排名第11位(共11家),截至2026-10-08;組內最高綜合評分為Halozyme Therapeutics Inc(74/100)。Closelook評分為研究日記讀數,不構成評等或投資建議。

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.